2025 International Congress

October 5-9, 2025. Honolulu, Hawaii.

View by Title View Categories

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Cerebrospinal fluid DOPA decarboxylase levels as a marker of disease severity in Parkinson’s Disease

K. Groenewald, L. van Hillegondsberg, T. Eisenstein, J. Klein, M. Hu (Oxford, United Kingdom)
Cerebrospinal fluid measured α-synuclein is related to metabolite profile in the serum and CSF

K. Paul, D. Jones, B. Ritz (Los Angeles, USA)
Cerebrotendinous Xanthomatosis successfully treated with Chenodeoxycholic Acid Supplementation

N. de Jong, J. Carr, D. Marais (Cape Town, South Africa)
Challenges in Airway Management after Deep Brain Stimulation in DYT1 Dystonia: a Case Report

CE. Wang, CF. Hu, YH. Chen, YF. Sung (Taipei City, Taiwan)
Challenges in Diagnosing and Managing Multiple System Atrophy in Low-Resource Settings: Insights from Nepal

A. Chandra, A. Chandra, S. Acharya (Kathmandu, Nepal)
Challenges in the Diagnosis and Management of Functional Movement Disorders in a Developing Nation: Insights from the Philippines

KA. Pañares, A. Lang, G. Saranza (Cebu, Philippines)
Changes in Cognitive Function with Deep Brain Stimulation in PD patients with and without Freezing of Gait

V. Basavatia, K. Kwei (New York, USA)
Changes in Functional Movement Disorders (FMD) Phenotype: A Retrospective Study

D. Marín-Medina, G. Lopez, M. Rossi, M. Merello (Buenos Aires, Argentina)
Changes in Inhibitory Control Differentiate Progressive Supranuclear Palsy from Early Parkinson’s Disease

B. Couto, F. Castano, J. Carrillo, M. Roca, A. Chade, O. Gershanik, G. Gomez-Arevalo (Buenos Aires, Argentina)
Changes in Motor States Throughout the Waking Day With Tavapadon in People With Parkinson’s Disease

R. Hauser, R. Pahwa, L. Harmer, A. Lind (Tampa, USA)

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z